A new study shows the Pfizer-BioNTech vaccine remains 90% effective at preventing COVID-19 hospitalizations for up to six months after being fully vaccinated, even with the more transmissible delta ...

Pfizer released additional data about its pill to treat COVID-19 that shows it was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few ...

WASHINGTON (AP) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% as the drug-maker joins the race to bring the first ...

Separately, per the Pfizer-issued report, interim analyses of an ongoing second study in standard-risk adults (EPIC-SR) showed a 70% reduction in hospitalization and no deaths in the treated ...

Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus, by 89%. The company also ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing infections in elementary school children. Details of the study were posted online Friday. FDA ...

Our team at the Advanced Photon Source have helped Pfizer create a COVID-19 treatment. The new drug candidate, Paxlovid, significantly reduced hospitalization and death in adult patients, according to ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

Pfizer CEO and Chair Albert Bourla, PhD, told CBS News that there is a “good chance” Pfizer will know if its experimental COVID-19 vaccine works by the end of October. While he couldn’t predict if ...